Strides Pharma Science Limited has notified shareholders that unclaimed dividends for the financial years 2018-19 and 2019-20 are due for transfer to the Investor Education and Protection Fund (IEPF). The company dispatched reminder letters to affected shareholders whose dividends have remained unclaimed for a period of seven consecutive years, urging them to claim the funds before the deadline to avoid the forfeiture of shares.

Transfer of Unclaimed Dividends

Pursuant to Section 124(6) of the Companies Act, 2013 and the Investor Education and Protection Fund Authority (Accounting, Audit, Transfer and Refund) Rules, 2016, the company is required to transfer unclaimed amounts to the IEPF. The specific dividends identified for transfer include the Final Dividend for 2018-19 and the Interim Dividend for 2019-20.

Shareholder Action Required

The company emphasized that shareholders must claim their unpaid dividends on or before September 3, 2026. Failure to do so will result in the transfer of the corresponding shares, whether held in physical or electronic form, to the designated demat account of the IEPF Authority. Once transferred, shareholders can claim both the shares and dividends from the IEPF, though the process involves specific procedures outlined by the authority.

Contact Information

Shareholders seeking clarification or assistance regarding the claim process can contact the company or its registrar, KFin Technologies Limited. The list of shares liable for transfer has been updated on the company’s website for reference.

Strides Pharma Science Limited has announced that the Scheme of Demerger involving Arco Lab Private Limited and Pivot Path Private Limited became effective from June 1, 2026. The demerger involves the transfer of the identified business of Arco Lab to Pivot Path. This development follows the approval granted by the Hon’ble National Company Law Tribunal (NCLT), Bengaluru Bench.

The company received the certified copy of the NCLT Order approving the Scheme of Demerger on May 25, 2026. Subsequently, the participating entities, Arco Lab and Pivot Path, filed the certified true copy of the order with the Registrar of Companies. This filing finalized the procedural requirements, rendering the scheme effective from the stipulated date.

Key Details of the Demerger

The following table summarizes the critical dates and entities involved in the Scheme of Demerger:

The Scheme of Demerger was approved by the NCLT, Bengaluru Bench, facilitating the transfer of the identified business from Arco Lab to Pivot Path. The intimation regarding the effective date was submitted to BSE Limited and The National Stock Exchange of India Limited under Regulation 30 of the SEBI Listing Regulations. Manjula Ramamurthy, Company Secretary of Strides Pharma Science Limited, signed the regulatory filing.